eli lilly tirzepatide cease and desist letter demands doctors stop selling copycat weight-loss drugs Legal Action by Eli Lilly

Liraglutide, injectable semaglutide, and dulaglutide have shown statistically significant reductions in major adverse cardiovascular events in patients with established cardiovascular disease or multiple risk factors

Its active ingredient is semaglutide, a GLP-1 receptor agonist that mimics a natural hormone involved in regulating insulin release, blood sugar, and appetite

Novo Nordisk has the same restrictions on its own direct-to-consumer website not linked through TrumpRx

Prescription drugs cannot be sold outside of a licensed pharmacy and should only be taken under the care of a healthcare professional because they are used to treat specific health conditions and may pose serious health risks